Coronary No-Reflow after Primary Percutaneous Coronary Intervention

Body of Paper

There is concern that the myocardium may suffer additional damage during the reperfusion phase. When blood flow is restored to an area that was previously ischemic, significant physiological and anatomical changes occur, such as tissue edema, neutrophil infiltration, microvascular damage, and subsequent reduction in microcirculatory flow. Therefore, the optimal reperfusion regimen for patients with STEMI should include ancillary and adjunctive treatments that reduce microvascular damage and protect the myocardial infarct zone, which contains cells at various stages of ischemia, necrosis, and apoptosis, in addition to the primary methods of restoring flow in the epicardial infarct artery (pharmacological or catheter-based) [2].

A coronary blood flow of less than TIMI 3, without severe stenosis, dissection, or an angiographically detected thrombus distal to the area of the IRA where PCI was performed, is referred to as no-reflow [3].

In the no-reflow zone, tissue edema, endothelial disruption, neutrophil and microthrombi plugging capillaries, complement component activation, inflammation from free radical production, and contracture of nearby myocytes cause the capillary structure to become disorganized. Coronary reperfusion facilitates these changes, making part of the no- reflow phenomenon attributable to reperfusion damage [4].

Various factors contribute to the no-reflow phenomenon, depending on whether microemboli are introduced into small arteries or arterioles, or if capillaries are destroyed or obstructed. Factors such as the length of coronary occlusion, the amount of myocardium supplied by the occluded artery, the patency of the infarct-related artery, the quality of collateral circulation, and the presence of preinfarction angina influence capillary obstruction, just as they influence myocardial necrosis following AMI [5].

Lipid-rich plaques susceptible to rupture during PCI are likely to generate microemboli. The release of plaque constituents, such as cholesterol crystals, macrophages, and platelet-fibrin complexes, may induce arteriole spasm, potentially causing additional microvascular blockage, thrombosis, and slow coronary flow. Typically, this restriction is temporary [6].

Clinical Consequences of the No-Reflow Event

Since the no-reflow phenomenon occurs after the local myocytes have already died, it is highly unlikely that function will later restore. A wide no-reflow zone is associated with reduced left ventricular contractile performance, and the absence of reflow also indicates a higher likelihood of acute complications following AMI. Patients exhibiting no-reflow represent the highest-risk subset of those undergoing reperfusion, with increased risks of both death and persistent congestive heart failure. A sizable no-reflow area may impede the infarct’s potential for healing and obstruct the distribution of therapeutic medications to that area. Transmural injury is common, and significant transmural injury may lead to early left ventricular dilatation and infarct expansion. The no-reflow phenomenon has been linked to cardiac rupture and ventricular arrhythmias, and it may adversely affect left ventricular remodeling following AMI. Follow-up studies have associated the no-reflow phenomenon with reduced ejection fraction, increased risk of cardiac death, and malignant arrhythmias, all of which have significant therapeutic implications [7].

Reperfusion therapy is no longer solely about opening the target artery; it also involves enhancing the patency of the microvasculature in the affected area [8].

Intense antiplatelet therapy with aspirin and clopidogrel, platelet glycoprotein-IIb/IIIa-receptor inhibitors, coronary vasodilators, and embolization prevention devices are examples of adjunctive therapies that reduce microemboli. Thrombolytic medications do not appear to improve microvascular performance [8].

Catheter-based devices include distal protection devices designed to capture embolic debris, and others that directly aspirate thrombus and plaque contents at the occlusion site. These devices fall into two categories: filter wire devices, which can be collapsed and withdrawn from the artery with the trapped debris, and balloon-occlusion devices, which are deployed at the distal site of a vulnerable plaque during PCI to temporarily occlude the vessel and then remove the debris with an aspiration catheter. Both types of devices can effectively remove embolic debris in most AMI patients undergoing emergency PCI. However, distal embolic protection does not always result in smaller infarcts, better event-free survival, or improved microvascular flow or reperfusion success [9].

The AngioJet rheolytic thrombectomy system (Possis Medical Inc., Minneapolis, MN) uses high-velocity, high- pressure saline jets through orifices at the distal tip of a catheter to create a localized low-pressure zone, removing thrombus using the Venturi-Bernoulli effect. This process entrains and dissociates bulky thrombus, creating a vacuum effect. AMI patients may experience reduced thrombus load after rheolytic thrombectomy with the AngioJet catheter. Long-term follow-up in a small study showed better outcomes for AMI patients treated with rheolytic thrombectomy compared to traditional primary angioplasty [10].

Research indicates that short-term, multiple coronary occlusions occurring shortly after prolonged myocardial ischemia are associated with a smaller myocardial infarct size compared to abrupt reperfusion. This cardioprotective measure is known as postconditioning. The protective process involves nitric oxide synthesis, opening of mitochondrial potassium channels, prevention of mitochondrial permeability transition pore opening, and activation of extracellular signal-regulated kinase. A similar strategy might be used in the cardiac catheterization laboratory after primary angioplasty in AMI patients to preserve the reperfused myocardium [11].

If myocytes and the microvasculature can be shielded from ischemic injury, reperfusion injury, or both, postischemic microvascular flow would increase, and functional and clinical outcomes would improve. Beyond its ability to dilate blood vessels, adenosine provides additional benefits that make it a viable treatment option. Adenosine preserves endothelial integrity, reduces neutrophil counts in infarct zones, and may have cardioprotective effects similar to ischemic preconditioning. Intracerebral delivery of 24-48 micrograms of adenosine improves ventricular performance and microvascular health in the infarct zone in AMI patients, enhancing clinical outcomes following percutaneous coronary intervention [12].

When administered prior to reperfusion, the mitochondrial potassium-channel opener nibandil, which has a nitrate component, has shown promising effects in AMI patients. This medication reduces calcium overload in myocytes, dilates coronary resistance arteries, decreases preload and afterload, and lessens neutrophil activation. Nicorandil may protect the heart from ischemic damage as the mitochondrial potassium channel is an end effector of the ischemic preconditioning pathway. Research has shown that patients who received intravenous nicorandil during reperfusion had improvements in microvascular perfusion, reduced infarct size, and better clinical outcomes [13].